410 related articles for article (PubMed ID: 17714966)
1. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
Tei E; Yamamoto H; Watanabe T; Miyazaki A; Nakadate T; Kato N; Mimura M
Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia.
Watanabe T; Miyazaki A; Katagiri T; Yamamoto H; Idei T; Iguchi T
J Am Geriatr Soc; 2005 Oct; 53(10):1748-53. PubMed ID: 16181175
[TBL] [Abstract][Full Text] [Related]
3. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H;
Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
[TBL] [Abstract][Full Text] [Related]
4. The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease.
Obermayr RP; Mayerhofer L; Knechtelsdorfer M; Mersich N; Huber ER; Geyer G; Tragl KH
Exp Gerontol; 2005 Mar; 40(3):157-63. PubMed ID: 15763392
[TBL] [Abstract][Full Text] [Related]
5. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
7. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T
J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
9. Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease.
Yamagata B; Watanabe T; Tomioka H; Kobayashi H; Nakano Y; Mimura M
Regul Pept; 2010 Aug; 163(1-3):137-42. PubMed ID: 20451565
[TBL] [Abstract][Full Text] [Related]
10. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
11. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease.
Hashimoto M; Yatabe Y; Kaneda K; Honda K; Ikeda M
Psychogeriatrics; 2009 Dec; 9(4):196-203. PubMed ID: 20377821
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
15. Cognitive predictors of donepezil therapy response in Alzheimer disease.
Saumier D; Murtha S; Bergman H; Phillips N; Whitehead V; Chertkow H
Dement Geriatr Cogn Disord; 2007; 24(1):28-35. PubMed ID: 17495473
[TBL] [Abstract][Full Text] [Related]
16. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
[TBL] [Abstract][Full Text] [Related]
17. Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD).
Giordano M; Dominguez LJ; Vitrano T; Curatolo M; Ferlisi A; Di Prima A; Belvedere M; Barbagallo M
Arch Gerontol Geriatr; 2010; 51(3):245-9. PubMed ID: 19969381
[TBL] [Abstract][Full Text] [Related]
18. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
Wattmo C; Hansson O; Wallin AK; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2008; 26(3):203-11. PubMed ID: 18769065
[TBL] [Abstract][Full Text] [Related]
19. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
